Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers. Microbix has closed a non-brokered private placement financing for gross proceeds of $750,000, comprising 2,893,516 units at $0.27 per unit. The Company has also reported its Q1/F2012 results, reflecting a return to normal customer demand after a one-time decline in sales a year ago. eResearch notes encouraging signs for the Company, with Microbix expecting a positive cash flow by the end of 2012, and with management demonstrating continued focus on the bottom line while progressing on all fronts. For more detail, read our Perspective here: Microbix Biosystems eResearch posts all its reports and articles on its website, www.eresearch.ca, and subscription is FREE. eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network. Contact:eResearch: Bob Weir, CFA, Director of Research Telephone: (416) 703-6258 Ext 221; E-mail: bweir@eresearch.ca